论文部分内容阅读
目的观察并探讨半量索非布韦联合达卡他韦治疗透析患者慢性丙型肝炎的疗效及安全性。方法规律透析患者合并慢性丙型肝炎39例,其中丙肝基因型1型8例。给予索非布韦半量联合达卡他韦常规剂量在透析结束时服用,疗程24周。观察停药后12周HCV应答率并记录不良反应。结果治疗2周时HCV-RNA阴转率(<15 IU/ml)为28例(71.8%),停药后12周病毒学应答率为100%。无因不良反应停药或减量患者。ALT/AST在治疗后显著下降,16例患者出现了HGB降低,平均降低(14.3±17.4)g/L,其中2例降低50 g/L以上。结论半量索非布韦联合达卡他韦治疗透析患者慢性丙型肝炎具有良好的疗效及安全性。
Objective To observe and discuss the efficacy and safety of semi-dose of sofosbuvir combined with daclatavir in the treatment of chronic hepatitis C in dialysis patients. Methods Regular dialytic patients with chronic hepatitis C in 39 cases, including hepatitis C genotype 1 in 8 cases. The dose of sofosbuvir given in combination with half-dose of dacitavir was given at the end of dialysis for 24 weeks. Observe the HCV response rate at 12 weeks after discontinuation and record the adverse reaction. Results The HCV-RNA negative conversion rate (<15 IU / ml) was 28 (71.8%) at 2 weeks and the virological response rate was 100% at 12 weeks after treatment. No due to adverse drug withdrawal or reduction patients. ALT / AST decreased significantly after treatment. HGB decreased in 16 patients with an average reduction of (14.3 ± 17.4) g / L, of which 2 cases decreased more than 50 g / L. Conclusion The treatment of chronic hepatitis C with dialysate and sebofovir combined with daclatavir has good efficacy and safety.